TB Alternative Assets Ltd. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the second quarter, Holdings Channel reports. The firm owned 39,600 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the period. Gilead Sciences accounts for about 1.3% of TB Alternative Assets Ltd.’s investment portfolio, making the stock its 12th largest position. TB Alternative Assets Ltd.’s holdings in Gilead Sciences were worth $2,803,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Hall Laurie J Trustee boosted its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Cable Hill Partners LLC boosted its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 541 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. boosted its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Finally, Penserra Capital Management LLC boosted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. 74.06% of the stock is owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (GILD) traded down 0.41% during mid-day trading on Friday, reaching $72.40. The company had a trading volume of 7,029,745 shares. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10. The stock has a 50 day moving average price of $72.36 and a 200 day moving average price of $68.77. The firm has a market capitalization of $94.55 billion, a PE ratio of 7.86 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the previous year, the firm earned $3.08 EPS. The business’s quarterly revenue was down 8.2% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by TB Alternative Assets Ltd.” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-tb-alternative-assets-ltd/1479678.html.

A number of research firms have commented on GILD. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday. Jefferies Group LLC reaffirmed a “hold” rating and set a $83.00 price objective on shares of Gilead Sciences in a research report on Thursday, July 27th. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Leerink Swann reaffirmed a “hold” rating and set a $74.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 25th. Finally, Cowen and Company reissued an “outperform” rating and issued a $90.00 target price on shares of Gilead Sciences in a research report on Thursday, July 27th. Twelve research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $80.31.

In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock worth $15,223,184 over the last three months. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.